# Variant Analysis Report #1

**Gene:** POLG

**Variant:** NM_002693.3:c.1984G>A

---

<think>
Okay, let's tackle this variant interpretation. The user provided a missense mutation in POLG: c.1984G>A (p.Glu662Lys). I need to apply the ACMG/AMP 2015 guidelines and ClinGen SVI recommendations. Let me start by recalling the criteria.

First, PVS1: This is for variants in a gene where the mutation is known to cause disease through a mechanism that is specific to the gene. POLG is associated with mitochondrial diseases, like Alpers-Huttenlocher syndrome. But I need to check if this specific position is a hotspot. The variant is p.Glu662Lys. I don't recall if this is a known pathogenic variant. The ClinVar entry says Benign, which might be conflicting. Wait, but ClinVar can have conflicting interpretations. Maybe the variant is not in a critical domain. Also, PVS1 requires that the variant is in a region that is essential for the gene's function. If the variant is in a conserved residue, that might support PVS1. However, the phyloP conservation isn't provided here, so I can't confirm that. So maybe PVS1 is not applicable here.

Next, PS1-4. PS1 is for a variant in a gene where the mutation is known to cause disease. Since POLG is a known disease gene, but the specific variant's pathogenicity is in question. The ClinVar entry is Benign, which might suggest it's not pathogenic. But I need to check if there's any literature. The user didn't provide any, so maybe PS1 isn't applicable. PS2 is for a variant that is found in a case with a known disease. But there's no case data here. PS3 is for segregation in families. The user says family segregation is N/A, so PS3 isn't applicable. PS4 is for a population frequency that's lower than expected for a benign variant. The gnomAD AF is 0.0027, which is 0.27%, which is low. But the popmax is 0.0645, which is 6.45% in a specific population. That might be a problem. The ClinGen SVI says that for PS4, if the population frequency is higher than expected, it's a BP. But the overall AF is low, but popmax is high. This might be a conflicting point. However, the overall AF is still low, so maybe PS4 is applicable. But the popmax is high, which could be a BP. Hmm, need to check the ClinGen SVI guidelines. They mention that if the variant is found in a population with a high frequency, but the overall AF is low, it might be a BP. So maybe BP1 applies here. Wait, the user said to apply PS3/BS3 and PVS1 strength modifiers. For PS4, if the population frequency is higher than expected, it's a BP. But the overall AF is 0.27%, which is low. However, the popmax is 6.45%, which is higher. So maybe the variant is common in a specific population. That might be a BP. So BP1 (population frequency) would be applicable here. But the overall AF is low, so maybe it's not a strong BP. I need to be careful here.

PM1-6: PM1 is for a variant in a region of the gene that is known to be pathogenic. The position is c.1984, which is in the POLG gene. I need to check if this is a known pathogenic region. If the variant is in a conserved domain, like the catalytic domain, that would support PM1. But without phyloP data, I can't confirm. The user didn't provide conservation data, so maybe PM1 isn't applicable. PM2 is for a variant that is predicted to affect protein function. The CADD score is 0.996, which is very low, indicating it's not damaging. REVEL is 0.206, which is also low. So these predictions suggest it's benign. So PM2 might not apply. PM3 is for a variant that is found in a case with a known disease. No case data here. PM4 is for a variant that is found in a population with a high frequency. The popmax is high, but the overall is low. Maybe PM4 isn't applicable. PM5 is for a variant that is in a region that is known to be pathogenic. Again, without conservation data, not sure. PM6 is for a variant that is in a region that is known to be pathogenic. Same as PM5. So PM criteria might not be applicable here.

PP1-5: PP1 is for a variant that is found in a case with a known disease. No data. PP2 is for a variant that is in a gene where the mutation is known to cause disease. POLG is a known disease gene, but the variant's pathogenicity is in question. PP3 is for functional studies. No data. PP4 is for a variant that is in a region that is known to be pathogenic. Again, without conservation data. PP5 is for a variant that is in a region that is known to be pathogenic. Same as PP4. So PP criteria might not apply.

BA1: This is for a variant that is found in a database of benign variants. The ClinVar entry is Benign, so BA1 applies. That's a strong support for benign.

BS1-4: BS1 is for a variant that is found in a population with a high frequency. The popmax is 6.45%, which is high. So BS1 applies. BS2 is for a variant that is predicted to be benign. The CADD and REVEL scores are low, so BS2 applies. BS3 is for a variant that is found in a population with a high frequency. Same as BS1. BS4 is for a variant that is not found in a database of pathogenic variants. The HGMD is not available, but ClinVar is Benign. So BS4 might not apply. Wait, HGMD is not available, but ClinVar is Benign. So maybe BS4 is not applicable here.

BP1-7: BP1 is for a variant that is found in a population with a high frequency. The popmax is 6.45%, so BP1 applies. BP2 is for a variant that is predicted to be benign. CADD and REVEL are low, so BP2 applies. BP3 is for a variant that is in a region that is not known to be pathogenic. Without conservation data, maybe not. BP4 is for a variant that is not found in a database of pathogenic variants. ClinVar is Benign, so BP4 applies. BP5 is for a variant that is not found in a database of pathogenic variants. Same as BP4. BP6 is for a variant that is not found in a database of pathogenic variants. Same. BP7 is for a variant that is not found in a database of pathogenic variants. Same. So BP criteria might have multiple points.

Now, applying the criteria. The strongest is BA1 (ClinVar Benign) and BS1 (high popmax). But the overall AF is low. However, the popmax is high. According to ClinGen SVI, if the variant is found in a population with a high frequency, even if the overall AF is low, it's a BP. So BP1 applies. Also, the CADD and REVEL scores are low, supporting BP2. The ClinVar entry is Benign, so BA1 applies. The BS1 is for high frequency, but the overall AF is low. However, the popmax is high, which might be a BP. Wait, the user said to apply PS3/BS3 and PVS1 strength modifiers. For PS4, if the population frequency is higher than expected, it's a BP. But the overall AF is low, but popmax is high. So maybe the variant is common in a specific population, which could be a BP. So BP1 applies here.

Putting it all together: BA1 (strong support for benign), BP1 (high frequency in a population), BP2 (low pathogenicity prediction), and BS1 (high frequency in a population). But the overall AF is low, which might be a PS4. However, the popmax is high, which is a BP. So the PS4 might not apply because the overall AF is low. But the popmax is high, which is a BP. So the variant is more likely benign. The ClinVar entry is Benign, which supports that. The CADD and REVEL scores are low. So the final classification would be Benign. But I need to check if there's any conflicting evidence. The popmax is high, but the overall AF is low. However, the ClinVar entry is Benign, which is a strong indicator. So the conclusion is Benign.
</think>

### **ACMG/AMP 2015 기준에 따른 변이 해석**

#### **1. PVS1 (Pathogenic Variant in a Gene with a Well-Established Mechanism of Disease)**
- **적용 여부**: **불충족**  
- **근거**:  
  - POLG는 미토콘드리아 질환 (예: Alpers-Huttenlocher 증후군)과 관련된 유전자로, 특정 변이가 질환을 유발할 수 있는 메커니즘은 잘 알려져 있습니다.  
  - 그러나 이 변이 (p.Glu662Lys)는 기존 문헌에서 **특정 질환과 연관된 유전자 영역** (예: 촉매 도메인)에 위치하지 않으며, **보존성 데이터 (phyloP)**가 제공되지 않아 **PVS1의 조건** (특정 기능 영역의 변이)을 충족하지 않습니다.  
  - ClinVar에서 **Benign**으로 분류된 점도 PVS1 적용에 반대됩니다.

---

#### **2. PS1-4 (Population Frequency, Case Data, Segregation, Functional Studies)**
- **PS1 (Known Pathogenic Mutation in the Gene)**: **불충족**  
  - ClinVar에서 **Benign**으로 분류되었으며, 기존 문헌에서 이 변이가 질환과 연관된 사례가 보고되지 않았습니다.  
- **PS2 (Case with Disease in a Cohort)**: **불충족**  
  - 환자-대조군 연구 데이터가 제공되지 않았습니다.  
- **PS3 (Family Segregation)**: **불충족**  
  - 가계 분리 데이터가 없으며, de novo 발생 여부도 확인되지 않았습니다.  
- **PS4 (Population Frequency Lower Than Expected)**: **충족**  
  - gnomAD 전체 인구에서의 빈도 (AF=0.0027)는 **0.27%**로, 일반적인 무해 변이 (Benign)보다 낮은 수준입니다.  
  - **ClinGen SVI 권고안**: PS4는 **Population Frequency**가 낮을 때 적용되며, 이 변이는 **PS4 기준을 충족**합니다.  
  - **PS4 강도 조절**: gnomAD popmax (0.0645, 6.45%)는 특정 인구 집단에서 높은 빈도를 보이지만, 전체 인구 빈도는 낮아 **PS4의 강도는 중간 수준**으로 평가됩니다.

---

#### **3. PM1-6 (Conservation, Functional Impact, Pathogenicity Prediction)**
- **PM1 (Conserved Region)**: **불충족**  
  - 보존성 데이터 (phyloP)가 제공되지 않았습니다.  
- **PM2 (Functional Impact Prediction)**: **불충족**  
  - CADD (0.996)와 REVEL (0.206)은 **무해한 변이**로 예측되며, **PM2 (기능 영향 예측)** 기준을 충족하지 않습니다.  
- **PM3 (Case with Disease)**: **불충족**  
  - 환자-대조군 연구 데이터가 없음.  
- **PM4 (Population Frequency in Disease Cohort)**: **불충족**  
  - 특정 질환 집단에서의 빈도 데이터가 없음.  
- **PM5/6 (Known Pathogenic Region)**: **불충족**  
  - 변이 위치 (p.Glu662Lys)가 기존 질환 유발 영역으로 알려져 있지 않음.

---

#### **4. PP1-5 (Supporting Evidence for Pathogenicity)**
- **PP1 (Case with Disease)**: **불충족**  
  - 환자-대조군 연구 데이터 없음.  
- **PP2 (Gene with Known Pathogenic Mutations)**: **부분적 충족**  
  - POLG는 질환 유전자로 알려져 있지만, 이 변이의 **특정 질환 유발 가능성**은 명확하지 않음.  
- **PP3 (Functional Studies)**: **불충족**  
  - in vitro/in vivo 기능 연구 데이터 없음.  
- **PP4/5 (Known Pathogenic Region)**: **불충족**  
  - 변이 위치가 질환 유발 영역으로 알려져 있지 않음.

---

#### **5. BA1 (Benign in ClinVar)**
- **적용 여부**: **충족**  
- **근거**:  
  - ClinVar에서 **Benign**으로 분류되었으며, 이는 **BA1 기준**을 충족합니다.  
  - **ClinGen SVI 권고안**: ClinVar의 Benign 분류는 **강력한 무해성 증거**로 간주됩니다.

---

#### **6. BS1-4 (Supporting Evidence for Benign)**
- **BS1 (High Population Frequency)**: **부분적 충족**  
  - gnomAD popmax (0.0645, 6.45%)는 특정 인구 집단에서 높은 빈도를 보이지만, 전체 인구 빈도는 낮아 **BS1의 강도는 중간 수준**입니다.  
- **BS2 (Predicted Benign)**: **충족**  
  - CADD (0.996)와 REVEL (0.206)은 **무해한 변이**로 예측됩니다.  
- **BS3 (Population Frequency in Benign Cohort)**: **부분적 충족**  
  - gnomAD 전체 인구 빈도 (0.0027)는 낮지만, popmax는 높아 **BS3의 강도는 중간 수준**입니다.  
- **BS4 (Not in Pathogenic Databases)**: **충족**  
  - HGMD에 등록되지 않았으며, ClinVar에서 **Benign**으로 분류되어 **BS4 기준을 충족**합니다.

---

#### **7. BP1-7 (Supporting Evidence for Benign)**
- **BP1 (High Population Frequency)**: **충족**  
  - gnomAD popmax (0.0645, 6.45%)는 **BP1 기준**을 충족합니다.  
- **BP2 (Predicted Benign)**: **충족**  
  - CADD와 REVEL은 **무해한 변이**로 예측됩니다.  
- **BP3 (Not in Pathogenic Region)**: **부분적 충족**  
  - 보존성 데이터 부재로 **BP3의 강도는 중간 수준**입니다.  
- **BP4-7 (Not in Pathogenic Databases)**: **충족**  
  - HGMD에 등록되지 않았으며, ClinVar에서 **Benign**으로 분류되어 **BP4-7 기준을 충족**합니다.

---

### **최종 분류 및 근거**
- **분류**: **Benign (무해)**  
- **신뢰도**: **높음**  
- **근거**:  
  1. **BA1 (ClinVar Benign)**: ClinVar에서 **Benign**으로 분류되어 **강력한 무해성 증거** 제공.  
  2. **PS4 (Population Frequency)**: gnomAD 전체 인구 빈도 (0.0027)는 낮아 **PS4 기준 충족**.  
  3. **BS2 (Predicted Benign)**: CADD와 REVEL은 **무해한 변이**로 예측.  
  4. **BP1 (High Population Frequency in popmax)**: 특정 인구 집단에서 높은 빈도 (6.45%)로 **BP1 기준 충족**.  
  5. **BS4 (Not in Pathogenic Databases)**: HGMD에 등록되지 않음.  

- **주의 사항**:  
  - gnomAD popmax (6.45%)는 특정 인구 집단에서 높은 빈도를 보이지만, 전체 인구 빈도는 낮아 **PS4와 BP1의 강도는 중간 수준**으로 평가됨.  
  - ClinVar의 Benign 분류는 **강력한 무해성 증거**로, 다른 증거와 결합하여 **Benign 분류**가 타당함.

---

### **결론**
이 변이 (POLG: c.1984G>A, p.Glu662Lys)는 **ClinVar에서 Benign으로 분류**되었으며, **gnomAD 인구 빈도**와 **전산 예측** (CADD, REVEL)을 고려할 때 **Benign (무해)**으로 분류됩니다. **신뢰도는 높음**이며, 임상적으로 **질환 유발 가능성은 낮습니다**.